tiprankstipranks
Trending News
More News >
Cts Corp. (CTS)
NYSE:CTS

CTS (CTS) AI Stock Analysis

Compare
127 Followers

Top Page

CTS

CTS

(NYSE:CTS)

Select Model
Select Model
Select Model
Neutral 68 (OpenAI - 5.2)
,
Neutral 68 (OpenAI - 5.2)
,
Neutral 68 (OpenAI - 5.2)
,
Neutral 68 (OpenAI - 5.2)
,
Neutral 68 (OpenAI - 5.2)
Rating:68Neutral
Price Target:
$50.00
▲(17.43% Upside)
Action:DowngradedDate:02/25/26
The score is driven primarily by solid and improving financial performance (higher margins, low leverage, positive free cash flow) and supportive 2026 guidance highlighting continued diversification and profitability gains. Offsetting factors are mixed near-term technical signals and a valuation profile that offers limited yield and no clear discount, alongside ongoing transportation and timing-related demand risks.
Positive Factors
Diversification of End Markets
CTS has shifted meaningful revenue away from transportation into medical, industrial and aerospace (diversified end markets ~57% of revenue). This structural mix lowers customer concentration, supports higher-margin product lines and improves revenue resilience across economic cycles.
Margin Expansion and Profitability
Sustained gross- and EBITDA-margin expansion (gross margin up to ~38% in 2025, adjusted EBITDA margin ~22.8%) signals durable improvements in pricing, product mix and operational efficiency. Higher structural margins increase earnings power and ability to fund R&D or returns.
Strong Cash Generation and Conservative Leverage
Consistent positive free cash flow (2020–2025), solid operating cash in 2025 and low leverage (debt-to-equity ~0.18–0.22) provide durable financial flexibility. This supports reinvestment, M&A optionality, and shareholder returns while cushioning cyclical downturns.
Negative Factors
Transportation End-Market Weakness
Transportation remains a large addressable market for CTS but showed a material decline driven by China and commercial vehicle softness. Continued exposure to auto production cycles and regional demand shifts can produce sustained revenue and margin volatility over the medium term.
Program Timing and Defense Bookings Volatility
Revenue tied to government contract awards (e.g., SideQuest) is lumpy and subject to funding/timing cycles. This program-dependent variability weakens revenue visibility, can shift backlog realization, and makes medium-term cash and earnings harder to predict.
Operating Cash Conversion Variability
Although free cash flow is positive, recurring instances where operating cash flow trails net income point to working-capital timing risk. That conversion volatility can limit reliable cash available for capex, buybacks or M&A in weaker demand periods.

CTS (CTS) vs. SPDR S&P 500 ETF (SPY)

CTS Business Overview & Revenue Model

Company DescriptionCTS Corporation (CTS) is a global leader in the design and manufacture of sensors, actuators, and electronic components. The company serves a diverse range of sectors, including automotive, aerospace and defense, communications, medical, and industrial markets. CTS's core products include piezoelectric sensors, timing devices, and advanced electronic components that enhance the performance and reliability of a wide array of applications.
How the Company Makes MoneyCTS makes money primarily by selling engineered components and subsystems to original equipment manufacturers (OEMs) and other customers. Revenue is generated from product sales across its operating segments: (1) Sensors, which includes various sensing solutions (e.g., for position, motion, pressure, or other parameters depending on application) sold into end markets such as automotive/transportation, industrial, and medical; (2) Connectivity Components, which includes electronic components that provide signal/power connectivity and related functions sold into electronics and communications-related applications; and (3) Actuators, which includes motion-control components (such as piezoelectric-based actuators and related devices) used in specialized industrial and other applications. Earnings are influenced by demand in end markets (notably automotive and industrial), customer program wins and production volumes, product mix and customization/engineering content, pricing and cost management, and the company’s ability to meet quality and reliability requirements for long-life and regulated applications. Specific material partnerships, customer concentration details, pricing terms, and segment-level contribution percentages: null.

CTS Earnings Call Summary

Earnings Call Date:Feb 10, 2026
(Q4-2025)
|
% Change Since: |
Next Earnings Date:Apr 23, 2026
Earnings Call Sentiment Positive
Overall the call emphasized clear progress on diversification, margin expansion, strong cash generation, and robust growth in medical and industrial end markets. These positives were tempered by transportation headwinds (notably in China and commercial vehicles), timing-related softness in SideQuest/defense bookings, and modest sequential revenue softness. Management provided modestly positive guidance for 2026 while acknowledging macro and supply-chain risks.
Q4-2025 Updates
Positive Updates
Quarterly and Full-Year Revenue Growth
Q4 sales of $137 million, up 9% year-over-year; full-year 2025 revenue of $541 million, up 5% versus $515 million in 2024.
Diversification Momentum
Diversified end markets grew 16% year-over-year in Q4 and were 59% of company revenue in Q4 (57% for the full year), supporting higher-margin revenue mix.
Medical Market Outperformance
Medical Q4 sales increased 41% year-over-year; full-year medical sales of $85 million, up 21% from $70 million in 2024; medical bookings up 37% in the quarter and book-to-bill ~1.07 for 2025.
Industrial Recovery and Bookings Strength
Industrial Q4 sales up 16% year-over-year; full-year industrial sales £140 million, up 12% from £125 million in 2024; industrial bookings up 22% in the quarter and full-year book-to-bill 1.11.
Aerospace & Defense Full-Year Growth and Strategic Wins
Aerospace & defense full-year sales $83 million, up 20% year-over-year, with multiple naval sonar/hydrophone and RF filter awards and new customers added, supporting future backlog.
Margin and Profitability Expansion
Adjusted gross margin expanded ~150 basis points (Q4 adjusted gross margin 39.1%; full-year adjusted gross margin 38.5%); adjusted EBITDA margin improved to 22.8%, up 40 basis points year-over-year.
Earnings Improvement
Q4 adjusted diluted EPS $0.62 versus $0.50 a year ago; full-year adjusted diluted EPS $2.23 versus $2.12 in 2024; Q4 GAAP diluted EPS $0.67 versus $0.38 prior-year quarter.
Strong Cash Generation and Capital Return
Operating cash flow of $29 million in Q4 and $102 million for the full year; cash balance $82 million and borrowings $58 million; repurchased ~398k shares (~$17 million) in Q4 and ~1.4 million shares (~$57 million) for the year; total returned $62 million to shareholders with $90 million remaining authorization.
Book-to-Bill and Backlog Indicators
Company-level book-to-bill of 1.03 in Q4 and 1.04 for the full year, indicating sustained customer demand; total book business approximately $1 billion at quarter end.
2026 Financial Guidance
Management provided 2026 guidance of $550 million to $580 million in sales and adjusted diluted EPS of $2.30 to $2.45, indicating expected modest growth and margin expansion.
Negative Updates
Transportation Revenue Decline
Transportation full-year sales were $234 million, down 7% versus $250 million in 2024 due to weak China market dynamics and commercial vehicle softness; Q4 transportation sales were essentially flat year-over-year.
SideQuest Timing and Lower-than-Expected Revenue
SideQuest contributed $22 million for the full year and $6 million in Q4, below expectations due to the timing of government contract awards and funding cycles, with recovery expected in 2026.
Defense Bookings Weakness in Quarter
Defense bookings were down in the fourth quarter (though full-year bookings were up 15%), indicating some near-term timing volatility tied to program decisions and funding.
Sequential Revenue Softness
Q4 sales were down 4% sequentially versus the prior quarter, highlighting some near-term demand variability.
Macro and Supply Chain Risks
Management cited headwinds including tariff impacts, slower EV investment cycles, commercial vehicle softness, and potential supply chain pressures related to rare earth metals and semiconductors, which could pressure transportation volumes and timing.
Slower Adoption of Some Transportation Technologies
E-brake and certain footwell solutions are seeing slower adoption as some OEMs recalibrate EV investments and launch schedules; some new product wins (e.g., floor hinge) have longer revenue ramps (first revenue expected in 2028).
Modest Tax Headwind to EPS
U.S. tax legislation changes had an adverse impact of approximately $0.03 on adjusted diluted EPS for 2025.
Company Guidance
For full-year 2026, assuming continuation of current market conditions, management guided sales of $550 million to $580 million and adjusted diluted EPS of $2.30 to $2.45; they expect solid demand across diversified end markets (medical momentum with increased therapeutic volumes in 2026, aerospace & defense revenue growth supported by backlog and SideQuest normalization, and industrial/distribution to remain healthy), while transportation production volumes are forecast to be flat to marginally down in line with IHS light vehicle estimates (North America 15–16 million units, Europe 16–17 million, China ~32 million), commercial vehicle demand generally soft with potential improvement in H2, floor‑hinge revenue not expected until 2028, next‑generation smart actuator qualification is progressing with further enhancements planned for 2026, and management noted no significant immediate supply‑chain disruptions from rare earths or semiconductors.

CTS Financial Statement Overview

Summary
Fundamentals are healthy with improving profitability (gross margin up to ~38% and net margin ~12% in 2025) and consistently positive free cash flow. Leverage is conservative (debt-to-equity ~0.18–0.22) with solid ROE (~11–12%). Offsets include uneven revenue momentum (declines in 2023–2024 before 2025 growth) and some cash-conversion volatility versus net income in several years.
Income Statement
78
Positive
Profitability is solid and improving: gross margin expanded from ~33% (2020) to ~38% (2025), and net margin improved to ~12% (2025) after a loss year in 2021. Earnings have been consistently positive since 2022 with healthy operating profitability (EBIT margin ~14–16% from 2022–2025). The key weakness is uneven top-line momentum—revenue declined in 2023 and 2024 before returning to growth in 2025, indicating demand cyclicality or customer/program timing risk.
Balance Sheet
74
Positive
Leverage looks conservative, with debt-to-equity staying low and stable (~0.18–0.22 from 2022–2025), and equity building over time. Returns on equity are healthy in the ~11–12% range (2022–2025), reflecting decent profitability on a strengthening capital base. The main drawback is the 2021 loss year (negative return on equity), which highlights that results can be sensitive in weaker operating environments, even if the current balance sheet is not heavily levered.
Cash Flow
71
Positive
Cash generation is generally strong: free cash flow is consistently positive (2020–2025) and has been growing recently (notably in 2025). Free cash flow tracks earnings reasonably well (free cash flow running at ~81–88% of net income from 2022–2025), supporting earnings quality. The weakness is that operating cash flow has not consistently covered net income (coverage below 1.0 in several years, including 2023 and 2025), suggesting working-capital timing or conversion volatility despite solid free cash flow.
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue541.32M515.54M550.55M586.87M512.92M
Gross Profit208.03M188.21M188.19M209.61M183.24M
EBITDA122.58M108.17M109.50M113.22M-32.58M
Net Income65.32M58.11M60.53M59.58M-41.87M
Balance Sheet
Total Assets764.31M766.11M741.17M748.49M664.46M
Cash, Cash Equivalents and Short-Term Investments82.30M94.33M163.88M156.91M141.47M
Total Debt121.91M117.09M96.86M109.36M74.75M
Total Liabilities212.53M235.26M214.34M242.26M200.88M
Stockholders Equity551.79M530.85M526.82M506.22M463.58M
Cash Flow
Free Cash Flow86.37M80.64M74.07M106.86M70.50M
Operating Cash Flow102.11M99.29M88.81M121.20M86.14M
Investing Cash Flow-18.51M-140.56M-18.10M-111.19M-15.90M
Financing Cash Flow-98.44M-27.93M-65.40M4.34M-20.71M

CTS Technical Analysis

Technical Analysis Sentiment
Negative
Last Price42.58
Price Trends
50DMA
50.68
Negative
100DMA
46.68
Negative
200DMA
43.93
Positive
Market Momentum
MACD
-1.51
Positive
RSI
30.53
Neutral
STOCH
7.36
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTS, the sentiment is Negative. The current price of 42.58 is below the 20-day moving average (MA) of 50.92, below the 50-day MA of 50.68, and below the 200-day MA of 43.93, indicating a neutral trend. The MACD of -1.51 indicates Positive momentum. The RSI at 30.53 is Neutral, neither overbought nor oversold. The STOCH value of 7.36 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTS.

CTS Risk Analysis

CTS disclosed 38 risk factors in its most recent earnings report. CTS reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

CTS Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
$2.56B5.8315.06%0.16%23.70%14.78%
68
Neutral
$1.32B19.3711.94%0.36%3.70%1.68%
68
Neutral
$987.21M93.639.64%-6.13%-76.92%
68
Neutral
$1.82B-27.26-5.07%-4.87%-235.48%
62
Neutral
$1.93B61.392.25%1.44%-2.93%-40.33%
61
Neutral
$37.18B12.37-10.20%1.83%8.50%-7.62%
47
Neutral
$178.92M-4.46-9.42%5.93%-9.51%29.57%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CTS
CTS
46.01
3.57
8.41%
BELFB
Bel Fuse Inc
205.11
131.13
177.24%
BHE
Benchmark Electronics
54.17
14.70
37.23%
DAKT
Daktronics
20.44
7.85
62.35%
MEI
Methode Electronics
5.05
-1.04
-17.08%
ROG
Rogers
101.82
24.03
30.89%

CTS Corporate Events

Business Operations and StrategyFinancial Disclosures
CTS Delivers Strong Q4 2025 Results Amid Diversification
Positive
Feb 10, 2026

On February 10, 2026, CTS reported strong fourth-quarter and full-year 2025 results, underscoring the success of its diversification strategy as sales to industrial, aerospace and defense, and medical end markets grew 16% and reached 57% of total revenue. Fourth-quarter sales rose 9% to $137 million, with net income jumping to $20 million and adjusted gross and EBITDA margins improving, despite a 1% decline in transportation sales.

For 2025 overall, CTS lifted sales 5% to $541 million, expanded net income to $65 million, and delivered higher diluted and adjusted diluted EPS alongside stronger cash generation of $102 million. While transportation revenues fell 7% for the year, management highlighted margin expansion, increased operating cash flow and new transportation product offerings and awards as reinforcing the company’s shift toward higher-quality, diversified earnings.

The most recent analyst rating on (CTS) stock is a Buy with a $59.00 price target. To see the full list of analyst forecasts on CTS stock, see the CTS Stock Forecast page.

Business Operations and StrategyFinancial Disclosures
CTS Highlights Growth Strategy in February 2026 Investor Update
Positive
Feb 10, 2026

CTS Corporation has presented an investor update for February 2026 outlining its financial profile and strategic positioning, highlighting last-12-month revenue of $541 million as of December 2025, an adjusted EBITDA margin of 23%, adjusted diluted EPS of $2.23 and a growing mix of diversified end markets now contributing 57% of sales. Management emphasized its goal of delivering about 10% total growth through a combination of mid‑single‑digit organic expansion and strategic M&A, leveraging megatrends such as automation, healthcare innovation and electrification, and underscored strong double‑digit year‑over‑year revenue growth in its industrial, medical, and aerospace and defense segments, signaling an ongoing shift away from transportation concentration and reinforcing CTS’s positioning in higher‑growth, technology‑driven niches.

The most recent analyst rating on (CTS) stock is a Buy with a $59.00 price target. To see the full list of analyst forecasts on CTS stock, see the CTS Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 25, 2026